Salsola Tragus Pollen

Dosage for Salsola Tragus Pollen extract is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Scratch/Prick Testing: Usually performed using a 1:10 or 1:20 w/v concentration. A single drop is applied to the skin, which is then pricked. Results are read after 15–20 minutes.
• Intradermal Testing: If prick tests are negative, a more sensitive intradermal test may be performed using a much more dilute solution (e.g., 1:1000 or 1:500 w/v).

Therapeutic Dosing (Immunotherapy)

Immunotherapy is divided into two phases:

1. 1Build-up (Escalation) Phase: Injections are typically given 1–2 times per week. The starting dose is usually very low (e.g., 0.05 mL of a 1:100,000 w/v dilution). The dose is gradually increased at each visit until the maintenance dose is reached.
2. 2Maintenance Phase: Once the target dose is achieved (often 0.5 mL of a 1:20 or 1:10 w/v concentration), the frequency of injections is decreased to once every 2–4 weeks. This phase usually lasts 3 to 5 years.

Salsola Tragus Pollen extract is generally considered safe for use in children, typically starting at age 5. Dosing protocols for children are similar to those for adults, though the starting dose may be even more conservative depending on the child's allergic history and the severity of their asthma. Children must be closely monitored for systemic reactions, as they may have more difficulty communicating early symptoms of anaphylaxis.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys. However, the patient's overall health and ability to tolerate a systemic reaction should be considered.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment, as the proteins are not metabolized by the liver.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (the primary treatment for a severe reaction) in patients with heart disease must be weighed against the benefits of immunotherapy.

Salsola Tragus Pollen extracts are for professional use only and must be administered by a healthcare provider in a clinical setting equipped to handle anaphylaxis.

• Administration Route: Subcutaneous injection only. It must NEVER be given intravenously.
• Injection Site: Usually the outer aspect of the upper arm. The site should be rotated between injections.
• Observation Period: Patients MUST remain in the medical office for at least 30 minutes following every injection to monitor for signs of a systemic reaction.
• Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If a dose is missed during the maintenance phase, the healthcare provider will determine the appropriate 'step-back' based on how much time has elapsed since the last injection. Never attempt to 'double up' on doses to make up for a missed one.

An overdose of allergenic extract occurs if the dose is increased too rapidly or if the wrong concentration is administered. The primary risk of overdose is a severe systemic reaction or anaphylaxis.

• Symptoms: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine, oxygen, and antihistamines. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your schedule or attempt to self-administer these injections without medical guidance.

Most patients undergoing immunotherapy with Salsola Tragus Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling: A 'wheal' or hard lump at the site of the injection. This may range from the size of a dime to the size of a silver dollar.
• Redness (Erythema): The skin around the injection site may turn red and feel warm to the touch.
• Itching (Pruritus): Intense itching at the injection site is very common and usually peaks within 1–2 hours.
• Tenderness: The arm may feel sore or bruised for 24–48 hours after the injection.

• Large Local Reactions: Swelling that exceeds 5–10 cm in diameter. While not systemic, these often require a dosage adjustment for the next visit.
• Fatigue: Some patients report feeling unusually tired for a few hours following their allergy shot.
• Mild Nasal Congestion: A slight 'flare' of hay fever symptoms shortly after the injection.

• Systemic Urticaria: Hives appearing on parts of the body away from the injection site (e.g., the trunk or legs).
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Generalized Pruritus: Itching all over the body without a visible rash.

> Warning: Stop taking Salsola Tragus Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Sudden wheezing, chest tightness, or difficulty breathing. This may indicate a severe bronchospasm.
• Throat Tightness: A feeling that the throat is closing or difficulty swallowing (laryngeal edema).
• Hypotension: A sudden drop in blood pressure, which may cause dizziness, lightheadedness, or fainting.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Rapid Pulse: A racing heart or palpitations accompanying other systemic symptoms.
• Uterine Contractions: In pregnant women, systemic reactions can occasionally trigger uterine activity.

There are no known cumulative toxicities associated with long-term use of Salsola Tragus Pollen extract. The goal of long-term use (3–5 years) is to produce a lasting change in the immune system. Once the treatment is successfully completed, many patients experience years of reduced allergy symptoms. However, some patients may experience a gradual return of symptoms after discontinuation, requiring a second course of therapy.

According to the FDA-approved labeling for allergenic extracts, including Salsola Tragus Pollen, there is a significant risk of severe systemic reactions.

Summary of Warning:

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Extracts should only be administered by healthcare providers experienced in the treatment of anaphylaxis and the use of emergency medications.
• Patients with unstable or severe asthma are at a higher risk for fatal reactions.
• Patients must be observed for at least 30 minutes in the office after every injection.
• Patients should be informed of the signs and symptoms of severe reactions and instructed to seek emergency care if they occur after leaving the clinic.

Report any unusual symptoms or delayed reactions (occurring hours after the injection) to your healthcare provider immediately.

Salsola Tragus Pollen extract is a potent biological product that must be handled with extreme caution. The primary safety concern is the unpredictability of systemic allergic reactions. Even patients who have tolerated previous injections well may suddenly experience a reaction due to factors like exercise, illness, or changes in the pollen count in the environment.

No FDA black box warnings for Salsola Tragus Pollen specifically, however, the entire class of allergenic extracts carries a general warning regarding anaphylaxis. This warning emphasizes that these products are not for self-administration and require immediate access to epinephrine and emergency resuscitation equipment. The risk is highest during the build-up phase and in patients with poorly controlled asthma.

• Anaphylaxis Risk: This is the most significant risk. Healthcare providers must ensure that the patient is not currently experiencing an acute asthma flare or high fever before administering an injection.
• Asthma Status: Patients with severe, unstable, or steroid-dependent asthma are at a significantly increased risk for a fatal systemic reaction. Asthma must be well-controlled before an injection is given.
• Beta-Blocker Use: Patients taking beta-blockers (used for heart conditions or migraines) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat. This is often considered a relative or absolute contraindication.
• Infection/Illness: Injections should be deferred if the patient has an acute respiratory infection or a significant febrile illness, as these conditions can lower the threshold for a systemic reaction.

While there are no routine blood tests (like liver or kidney function) required for Salsola Tragus Pollen, clinical monitoring is intensive:

• Pre-Injection Assessment: The provider should check the patient's current symptoms and any reactions to the previous dose.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before the injection to ensure lung function is stable.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic is standard practice.

In general, Salsola Tragus Pollen does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been fully cleared by a medical professional and are no longer experiencing symptoms or medication side effects.

There is no direct chemical interaction between alcohol and Salsola Tragus Pollen. However, alcohol consumption can cause vasodilation and may potentially increase the rate of absorption of the extract or mask early symptoms of an allergic reaction. Patients are generally advised to avoid heavy alcohol use on the day of their injections.

Unlike many medications, Salsola Tragus Pollen does not require a tapering period to avoid withdrawal. However, stopping immunotherapy prematurely will likely result in the return of allergy symptoms. If treatment is interrupted for more than a few weeks, the provider will need to restart at a lower dose to ensure safety.

> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Salsola Tragus Pollen.

• Beta-Adrenergic Blockers (Beta-Blockers): This includes medications like propranolol, atenolol, or metoprolol. These drugs can interfere with the action of epinephrine, which is the life-saving treatment for anaphylaxis. If a patient on a beta-blocker has a severe reaction to Salsola Tragus Pollen, the standard doses of epinephrine may fail to reverse the symptoms, leading to potentially fatal outcomes.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (like lisinopril or enalapril) may be at an increased risk for more severe systemic reactions during immunotherapy, though the data is less definitive than with beta-blockers.
• MAO Inhibitors (MAOIs): Drugs like phenelzine or tranylcypromine can potentiate the effects of sympathomimetic amines (like epinephrine), which could complicate the treatment of an allergic reaction.

• Antihistamines: While many patients take antihistamines (like cetirizine or loratadine) to manage their symptoms, these drugs can mask the early signs of a systemic reaction (like itching or hives) or suppress the results of diagnostic skin testing. Patients are typically told to stop antihistamines 3–7 days before skin testing.
• Tricyclic Antidepressants: Similar to MAOIs, these can affect how the body responds to epinephrine during an emergency.

• No Specific Food Restrictions: There are no known direct food interactions with Salsola Tragus Pollen. However, patients with 'Oral Allergy Syndrome' may find that certain foods (like melons or peaches) trigger itching in the mouth due to cross-reactivity with weed pollens. This is a separate phenomenon from the injection treatment.

• Immunosuppressants: Herbal supplements that claim to 'boost' or 'suppress' the immune system (such as Echinacea or high-dose corticosteroids) could theoretically interfere with the goal of immunotherapy, which is a controlled modulation of the immune response. Always inform your doctor of any supplements you are taking.

• Skin Test Suppression: As mentioned, antihistamines, H2 blockers (like famotidine), and certain antidepressants can cause false-negative results on skin tests for Salsola Tragus Pollen.
• Specific IgE (n-CAP/RAST): Immunotherapy will eventually cause a decrease in skin test reactivity and may lead to changes in serum IgE and IgG4 levels, which are expected therapeutic outcomes rather than 'interactions.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is essential for your safety during immunotherapy.

Conditions where Salsola Tragus Pollen must NEVER be used include:

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values or those with frequent acute exacerbations are at an unacceptably high risk for fatal bronchospasm following an injection.
• Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. The cardiovascular stress of a systemic reaction or the administration of epinephrine could be fatal.
• Hypersensitivity to Excipients: Patients with a known severe allergy to glycerin, phenol (a preservative), or other components of the extract solution.

Conditions requiring careful risk-benefit analysis:

• Beta-Blocker Therapy: As discussed, this makes treating a reaction difficult. If the beta-blocker cannot be stopped, the allergist must decide if the allergy is severe enough to warrant the risk.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare of their condition if the immune system is stimulated by immunotherapy.
• Malignancy: Patients undergoing active chemotherapy or with certain types of cancer are generally not started on immunotherapy.

Patients allergic to Salsola Tragus (Russian Thistle) often show cross-sensitivity to other members of the Amaranthaceae/Chenopodiaceae family, such as:

• Kochia (Burning Bush)
• Lamb’s Quarters
• Pigweed

If a patient is highly sensitive to one of these, the healthcare provider may adjust the starting dose of Salsola Tragus Pollen to avoid an over-reaction.

> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung health, before prescribing Salsola Tragus Pollen.

• FDA Category: Not formally assigned, but generally handled with caution.
• Risk Summary: It is generally recommended NOT to start Salsola Tragus Pollen immunotherapy during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen) or trigger uterine contractions. However, if a woman is already on a maintenance dose and is tolerating it well, many allergists allow the treatment to continue at the same or a slightly reduced dose. Dosage increases are strictly avoided during pregnancy.

• Passage into Milk: Allergenic extracts are large proteins that are digested in the infant's gut if they were to pass into milk; however, there is no evidence that they reach significant levels in breast milk.
• Safety: Immunotherapy is considered safe for breastfeeding mothers. There are no known adverse effects on the nursing infant.

• Approved Age: Generally safe for children 5 years and older.
• Considerations: Younger children may have difficulty cooperating with the injection schedule or expressing the early symptoms of a reaction. The benefit of preventing the 'allergic march' (the progression from rhinitis to asthma) often justifies the use of immunotherapy in children.

• Risk Profile: Patients over 65 are at a higher risk for underlying cardiovascular disease. This makes them more vulnerable to the effects of a systemic reaction and less able to tolerate the epinephrine required to treat it. A thorough cardiac evaluation is often recommended for older adults before starting Salsola Tragus Pollen extracts.

• Dosing: No adjustments are needed for renal impairment. The proteins are not cleared by the kidneys, and there is no evidence of nephrotoxicity.

• Dosing: No adjustments are needed for hepatic impairment. The liver is not involved in the processing or elimination of these allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant or planning to become pregnant.

Salsola Tragus Pollen extract acts as an immunomodulator. The primary allergens in the pollen, such as Sal t 1 (a pectin methylesterase), are recognized by the immune system. In an allergic individual, this recognition leads to a Th2-cell response. Immunotherapy with the extract forces the immune system to re-evaluate the allergen. Through repeated exposure, the body increases the production of T-regulatory cells (Tregs) that secrete IL-10 and TGF-beta. These cytokines suppress the allergic inflammation and signal B-cells to switch from producing IgE to producing IgG4, which acts as a protective 'decoy' antibody.

• Onset of Effect: Clinical improvement is rarely immediate. It typically takes 3–6 months of build-up therapy before a patient notices a reduction in symptoms.
• Duration of Effect: The goal is permanent immunological tolerance. Studies suggest that a full 3–5 year course of treatment can provide symptom relief for many years after the injections are stopped.
• Tolerance: Unlike many drugs, 'tolerance' in this context is the desired therapeutic effect (immune tolerance), not a loss of drug efficacy.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous injection, local processing) |

| Protein Binding | N/A (Processed by APCs) |

| Half-life | Days (Immunological effect lasts weeks) |

| Tmax | 1–2 hours (For local absorption) |

| Metabolism | Cellular Proteolysis |

| Excretion | Not renally or fecally excreted |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from the pollen of Salsola tragus.
• Solubility: Highly soluble in aqueous buffers and saline solutions.
• Molecular Weight: Varies; major allergens like Sal t 1 are approximately 35–45 kDa.

Salsola Tragus Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It belongs to the broader therapeutic category of Allergen Immunotherapy (AIT) products. It is related to other weed pollen extracts such as Ragweed, Sagebrush, and Pigweed extracts.